ClinicalTrials.gg
CompletedNCT07948473Updated Nov 19, 2026

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets in Healthy Volunteers

A Phase 1 interventional study of Metformin hydrochloride extended-release tablets 1g in Diabetes Mellitus Type 2, sponsored by The Affiliated Hospital Of Guizhou Medical University. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Affiliated Hospital Of Guizhou Medical University · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2024, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 912 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
570th of 769
60 · median 192
Started
2024
with 83 others
Phase 1
123 of 912
12 open now
Registered
912th of 912
by date

Among the 912 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 570th largest by enrollment of the 769 interventional ones that give a count, is one of 84 that started in 2024, is one of 123 in phase 1, and was the 912th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 912 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 912 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

Metformin is widely used for the treatment of type 2 diabetes mellitus (T2DM). Its glucose-lowering effects involve suppression of hepatic glucose production and improvements in insulin sensitivity.

The purpose of this study was to evaluate the bioequivalence, pharmacokinetic characteristics, and safety of a test metformin hydrochloride extended-release tablet (1 g) compared with the reference formulation in healthy Chinese subjects under fasting and fed conditions.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Chinese male or female subjects aged ≥18 years;
  • Body weight ≥50 kg for males and ≥45 kg for females, with a (BMI) of 19.0-26.0 kg/m² (inclusive), calculated as body weight (kg) divided by height squared (m²);
  • Subjects who were able to understand and comply with the study procedures, voluntarily agreed to participate in the study, and provided written .

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history or presence of diseases considered by the investigator, including but not limited to disorders of the cardiovascular, digestive, genitourinary, respiratory, hematological, endocrine, immune, neuropsychiatric, or musculoskeletal systems. Particular attention was given to gastrointestinal dysfunction (such as diarrhea or constipation), peptic ulcers, gastrointestinal surgery, or other conditions that might affect drug absorption, distribution, metabolism, or excretion.
  • Subjects with clinically significant abnormalities identified by the investigator during physical examination, vital sign assessment, laboratory tests, 12-lead electrocardiography (), or frontal chest X-ray examination.
  • Subjects with a history of hypoglycemia.
  • Subjects who had undergone surgery within 3 months before screening, planned to undergo surgery during the study, or had previously undergone any surgical procedure that could affect drug absorption, distribution, metabolism, or excretion.
  • Subjects prone to nausea, vomiting, or diarrhea, or who had experienced severe vomiting or diarrhea within 1 week before screening.
  • Subjects with a history of clinically significant food or drug allergies, as determined by the investigator; known to metformin or any of its ; or a history of allergic disorders, including asthma, urticaria, or eczematous dermatitis.
  • Subjects with positive test results for surface antigen (HBsAg), hepatitis B e antigen (HBeAg), virus (HCV) antibodies, (HIV), or Treponema pallidum antibodies (TP-Ab).
  • Subjects with a history of drug abuse within 12 months before screening or a positive urine drug screening result.
  • Subjects who regularly consumed alcohol within 6 months before screening, defined as an average consumption of more than 14 units of alcohol per week (1 unit ≈ 285 mL of beer containing 3.5% alcohol, 25 mL of spirits containing 40% alcohol, or 85 mL of wine containing 12% alcohol); who were unable to abstain from alcohol from 48 hours before dosing throughout the study; or who had a positive breath alcohol test.
  • Subjects who smoked an average of ≥5 cigarettes per day within 3 months before screening or were unable to abstain from smoking from 48 hours before the first dose until the end of the study.
  • Subjects who had received any blood transfusion or blood products within 3 months before screening or had experienced blood loss of ≥400 mL due to other causes, excluding physiological menstrual blood loss in female subjects.
  • Subjects who had participated in another clinical trial within 3 months before screening.
  • Subjects who had used any prescription medications, over-the-counter medications, traditional Chinese medicines, or health supplements within 4 weeks before screening.
  • Subjects who had received any vaccination within 4 weeks before screening or planned to receive a vaccination during the study.
  • Subjects with special dietary requirements or who were unable to comply with the prescribed diet and related restrictions (e.g., intolerance to the standardized meal or high-fat meal); or who had consumed xanthine- or caffeine-rich beverages or foods (such as coffee, tea, cola, chocolate, or animal liver), certain fruits or fruit juices that might affect drug metabolism (such as grapefruit, pomelo, mango, or dragon fruit), or alcohol-containing foods or beverages within 48 hours before administration of the product.
  • Subjects with lactose or galactose intolerance.
  • Female subjects who were pregnant or breastfeeding, or who had a positive pregnancy test before the study; male or female subjects who were unable or unwilling to use effective approved by the investigator during the required study period; subjects who planned to donate sperm or ova from the time of signing the form until 3 months after the last dose; or female subjects who had engaged in sexual intercourse without effective contraception within 14 days before signing the informed consent form.
  • Subjects who had difficulty swallowing tablets.
  • Subjects who were unable to tolerate venipuncture or had a history of needle-related or blood-related syncope.
  • Subjects considered unsuitable for participation in the study by the investigator or who voluntarily withdrew from the study for personal reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Fasted Cohort: T-R

    Drug: Metformin hydrochloride extended-release tablets 1g

  • Experimental
    Fasted Cohort: R-T

    Drug: Metformin hydrochloride extended-release tablets 1g

  • Experimental
    Fed Cohort: T-R

    Drug: Metformin hydrochloride extended-release tablets 1g

  • Experimental
    Fed Cohort: R-T

    Drug: Metformin hydrochloride extended-release tablets 1g

Interventions

  • DrugMetformin hydrochloride extended-release tablets 1g

    Oral metformin hydrochloride extended-release tablets, Once every seven days,One cycle T drug, one cycles R drug

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The with-subject standard deviation of the pharmacokinetic parameter Cmax of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

    Time frame: From predose to 48 hours postdose in each treatment period

  2. Area Under the Plasma Concentration-Time curve from 0 to t (AUC0-t)

    The with-subject standard deviation of the pharmacokinetic parameter AUC0-t of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

    Time frame: From predose to 48 hours postdose in each treatment period

  3. Area Under the Plasma Concentration-Time Curve From 0 to Infinity (AUC0- ∞)

    The with-subject standard deviation of the pharmacokinetic parameter AUC0- ∞ of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

    Time frame: From predose to 48 hours postdose in each treatment period

07

Study locations

1 site
  • Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University
    Guiyang, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2024, 1 month.

Of 62 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 1 month is below that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartActual
Mar 18, 2024
Primary completionActual
Apr 28, 2024
CompletionActual
May 17, 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948473
Lead sponsor
The Affiliated Hospital Of Guizhou Medical University
Responsible party
Yan He (Chief Physician, The Affiliated Hospital Of Guizhou Medical University) — Principal investigator
First posted
Nov 19, 2026
Start date
Mar 18, 2024
Primary completion
Apr 28, 2024
Completion
May 17, 2024
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion